CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...